tiprankstipranks
Advertisement
Advertisement

CCCC Stock Latest News

C4 Therapeutics Realigns Finance Leadership After Officer Departure
Company AnnouncementsC4 Therapeutics Realigns Finance Leadership After Officer Departure
6d ago
8K
CCCC
C4 Therapeutics reports Q1 EPS (20c), consensus (26c)
PremiumThe Fly
C4 Therapeutics reports Q1 EPS (20c), consensus (26c)
9d ago
CCCC
C4 Therapeutics Reports Q1 Results and Clinical Advancements
PremiumCompany Announcements
C4 Therapeutics Reports Q1 Results and Clinical Advancements
9d ago
8K
CCCC
Is CCCC a Buy, Before Earnings?
PremiumPre-Earnings
Is CCCC a Buy, Before Earnings?
11d ago
CCCC
C4 Therapeutics Expands Roche Collaboration with New DAC Deal
PremiumCompany Announcements
C4 Therapeutics Expands Roche Collaboration with New DAC Deal
1M ago
8K
CCCC
C4 Therapeutics expands long-term partnership with Roche
PremiumThe FlyC4 Therapeutics expands long-term partnership with Roche
1M ago
CCCC
CHRO
C4 Therapeutics doses first patient in cemsidomide trial
Premium
The Fly
C4 Therapeutics doses first patient in cemsidomide trial
2M ago
CCCC
C4 Therapeutics price target raised to $7 from $5 at Barclays
Premium
The Fly
C4 Therapeutics price target raised to $7 from $5 at Barclays
3M ago
CCCC
C4 Therapeutics: Cemsidomide’s Best-in-Class CELMoD Potential and De‑Risking Clinical Momentum Support Buy Rating
PremiumRatings
C4 Therapeutics: Cemsidomide’s Best-in-Class CELMoD Potential and De‑Risking Clinical Momentum Support Buy Rating
3M ago
CCCC
C4 Therapeutics reports Q4 EPS (18c), consensus (34c)
PremiumThe Fly
C4 Therapeutics reports Q4 EPS (18c), consensus (34c)
3M ago
CCCC
C4 Therapeutics price target raised to $30 from $20 at Brookline
PremiumThe Fly
C4 Therapeutics price target raised to $30 from $20 at Brookline
3M ago
CCCC
C4 Therapeutics announces first patient dosed in Phase 2 MOMENTUM trial
PremiumThe Fly
C4 Therapeutics announces first patient dosed in Phase 2 MOMENTUM trial
3M ago
CCCC
CCCC Upcoming Earnings Report: What to Expect?
PremiumPre-EarningsCCCC Upcoming Earnings Report: What to Expect?
3M ago
CCCC
C4 Therapeutics’ Phase 2 Myeloma Trial Moves Forward, Setting Up a Key Catalyst for CCCC Investors
Premium
Company Announcements
C4 Therapeutics’ Phase 2 Myeloma Trial Moves Forward, Setting Up a Key Catalyst for CCCC Investors
4M ago
CCCC
C4 Therapeutics Unveils Multi-Year Cemsidomide Clinical Strategy
Premium
Company Announcements
C4 Therapeutics Unveils Multi-Year Cemsidomide Clinical Strategy
4M ago
8K
CCCC
C4 Therapeutics outlines milestones through 2028
PremiumThe Fly
C4 Therapeutics outlines milestones through 2028
4M ago
CCCC
C4 Therapeutics Sets Up New Combination Trial in Multiple Myeloma: What Investors Should Watch
PremiumCompany Announcements
C4 Therapeutics Sets Up New Combination Trial in Multiple Myeloma: What Investors Should Watch
4M ago
CCCC
C4 Therapeutics price target lowered to $5 from $10 at Barclays
PremiumThe Fly
C4 Therapeutics price target lowered to $5 from $10 at Barclays
5M ago
CCCC
C4 Therapeutics’ Innovative Drug Development and Promising Clinical Trials Support Buy Rating
PremiumRatings
C4 Therapeutics’ Innovative Drug Development and Promising Clinical Trials Support Buy Rating
6M ago
CCCC
C4 Therapeutics initiated with a Buy at TD Cowen
PremiumThe FlyC4 Therapeutics initiated with a Buy at TD Cowen
6M ago
CCCC
C4 Therapeutics files $400M mixed securities shelf
Premium
The Fly
C4 Therapeutics files $400M mixed securities shelf
6M ago
CCCC
C4 Therapeutics Reports Q3 2025 Financial Results
Premium
Company Announcements
C4 Therapeutics Reports Q3 2025 Financial Results
7M ago
CCCC

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >